Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L J van Warmerdam

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The Netherlands Journal of Medicine|July 1, 1997
Tailor-made chemotherapy for cancer patientsL J van Warmerdam
Seminars in Oncology|February 1, 1997
An overview of the clinical pharmacology of topotecanM J Dennis, J H Beijnen, L B Grochow, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Limited-sampling models for anticancer agentsL J van Warmerdam, W W ten Bokkel Huinink, R A Maes, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combinationL J van Warmerdam, S Rodenhuis, O van Tellingen, et al.
British Journal of Cancer|April 1, 1996
Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell supportL J van Warmerdam, S Rodenhuis, E van der Wall, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
The use of the Calvert formula to determine the optimal carboplatin dosageL J van Warmerdam, S Rodenhuis, W W ten Bokkel Huinink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1994
Limited sampling models for topotecan pharmacokineticsL J van Warmerdam, J Verweij, H Rosing, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatinL J van Warmerdam, S Rodenhuis, W W ten Bokkel Huinink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1994
Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and responseW W ten Bokkel Huinink, L J van Warmerdam, A C Dubbelman, et al.
Cancer Chemotherapy and Pharmacology|April 1, 1999
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimenV R Panday, L J van Warmerdam, M T Huizing, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The Netherlands Journal of Medicine|July 1, 1997
Tailor-made chemotherapy for cancer patientsL J van Warmerdam
Seminars in Oncology|February 1, 1997
An overview of the clinical pharmacology of topotecanM J Dennis, J H Beijnen, L B Grochow, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Limited-sampling models for anticancer agentsL J van Warmerdam, W W ten Bokkel Huinink, R A Maes, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combinationL J van Warmerdam, S Rodenhuis, O van Tellingen, et al.
British Journal of Cancer|April 1, 1996
Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell supportL J van Warmerdam, S Rodenhuis, E van der Wall, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1995
The use of the Calvert formula to determine the optimal carboplatin dosageL J van Warmerdam, S Rodenhuis, W W ten Bokkel Huinink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1994
Limited sampling models for topotecan pharmacokineticsL J van Warmerdam, J Verweij, H Rosing, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1996
Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatinL J van Warmerdam, S Rodenhuis, W W ten Bokkel Huinink, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1994
Intraperitoneal-administered carboplatin in patients with ovarian cancer; influence of a dwell-time on toxicity and responseW W ten Bokkel Huinink, L J van Warmerdam, A C Dubbelman, et al.
Cancer Chemotherapy and Pharmacology|April 1, 1999
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimenV R Panday, L J van Warmerdam, M T Huizing, et al.
Pageof 3